These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14980670)

  • 1. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs.
    Jia ZJ; Wu Y; Huang W; Zhang P; Clizbe LA; Goldman EA; Sinha U; Arfsten AE; Edwards ST; Alphonso M; Hutchaleelaha A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1221-7. PubMed ID: 14980670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.
    Jia ZJ; Wu Y; Huang W; Zhang P; Song Y; Woolfrey J; Sinha U; Arfsten AE; Edwards ST; Hutchaleelaha A; Hollennbach SJ; Lambing JL; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1229-34. PubMed ID: 14980671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
    Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues.
    Qiao JX; Cheng X; Smallheer JM; Galemmo RA; Drummond S; Pinto DJ; Cheney DL; He K; Wong PC; Luettgen JM; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1432-7. PubMed ID: 17174550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.
    Varnes JG; Wacker DA; Pinto DJ; Orwat MJ; Theroff JP; Wells B; Galemo RA; Luettgen JM; Knabb RM; Bai S; He K; Lam PY; Wexler RR
    Bioorg Med Chem Lett; 2008 Jan; 18(2):749-54. PubMed ID: 18054227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent factor Xa inhibitors.
    Jia ZJ; Scarborough RM; Zhang P; Halfon S; Arfsten AE; Sinha U; Zhu BY
    Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):1004-7. PubMed ID: 19721266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
    Fevig JM; Cacciola J; Buriak J; Rossi KA; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3755-60. PubMed ID: 16682200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors.
    Franciskovich JB; Masters JJ; Weber WW; Klimkowski VJ; Chouinard M; Sipes PR; Johnson LM; Snyder DW; Chastain MK; Craft TJ; Towner RD; Gifford-Moore DS; Froelich LL; Smallwood JK; Foster RS; Smith GF; Liebeschuetz JW; Murray CW; Young SC
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6910-3. PubMed ID: 17976987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.
    Zhang P; Bao L; Zuckett JF; Goldman EA; Jia ZJ; Arfsten A; Edwards S; Sinha U; Hutchaleelaha A; Park G; Lambing JL; Hollenbach SJ; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Feb; 14(4):983-7. PubMed ID: 15013006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity.
    Zhang P; Bao L; Zuckett JF; Jia ZJ; Woolfrey J; Arfsten A; Edwards S; Sinha U; Hutchaleelaha A; Lambing JL; Hollenbach SJ; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Feb; 14(4):989-93. PubMed ID: 15013007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides.
    Jia ZJ; Wu Y; Huang W; Goldman E; Zhang P; Woolfrey J; Wong P; Huang B; Sinha U; Park G; Reed A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1651-5. PubMed ID: 12039583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
    Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
    Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors.
    Imaeda Y; Miyawaki T; Sakamoto H; Itoh F; Konishi N; Hiroe K; Kawamura M; Tanaka T; Kubo K
    Bioorg Med Chem; 2008 Mar; 16(5):2243-60. PubMed ID: 18077174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
    Quan ML; Lam PY; Han Q; Pinto DJ; He MY; Li R; Ellis CD; Clark CG; Teleha CA; Sun JH; Alexander RS; Bai S; Luettgen JM; Knabb RM; Wong PC; Wexler RR
    J Med Chem; 2005 Mar; 48(6):1729-44. PubMed ID: 15771420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa.
    Kochanny MJ; Adler M; Ewing J; Griedel BD; Ho E; Karanjawala R; Lee W; Lentz D; Liang AM; Morrissey MM; Phillips GB; Post J; Sacchi KL; Sakata ST; Subramanyam B; Vergona R; Walters J; White KA; Whitlow M; Ye B; Zhao Z; Shaw KJ
    Bioorg Med Chem; 2007 Mar; 15(5):2127-46. PubMed ID: 17227710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Koch S; Rossi KA; Alexander RS; Smallwood A; Wong PC; Rendina AR; Luettgen JM; Knabb RM; He K; Xin B; Wexler RR; Lam PY
    J Med Chem; 2007 Nov; 50(22):5339-56. PubMed ID: 17914785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Quan ML; Han Q; Galemmo RA; Amparo E; Wells B; Ellis C; He MY; Alexander RS; Rossi KA; Smallwood A; Wong PC; Luettgen JM; Rendina AR; Knabb RM; Mersinger L; Kettner C; Bai S; He K; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4141-7. PubMed ID: 16730984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa.
    Qiao JX; Cheney DL; Alexander RS; Smallwood AM; King SR; He K; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4118-23. PubMed ID: 18550370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR.
    Zhang P; Bao L; Fan J; Jia ZJ; Sinha U; Wong PW; Park G; Hutchaleelaha A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2186-9. PubMed ID: 19297158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors.
    Varnes JG; Wacker DA; Jacobson IC; Quan ML; Ellis CD; Rossi KA; He MY; Luettgen JM; Knabb RM; Bai S; He K; Lam PY; Wexler RR
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6481-8. PubMed ID: 17933529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.